Fresenius SE & Co. (FSNUY)
(Delayed Data from OTC)
$7.30 USD
+0.19 (2.67%)
Updated Apr 19, 2024 03:59 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Price, Consensus and EPS Surprise
FSNUY 7.30 +0.19(2.67%)
Will FSNUY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FSNUY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FSNUY
Is Fresenius SE & Co. (FSNUY) a Great Value Stock Right Now?
FSNUY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for FSNUY
CVS favors Humira copycats hurting AbbVie’s market share: Evercore
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.
Fresenius SE launches biosimilar of Roche's Actemra
AbbVie keeps Humira market share near 100% despite biosimilars: report
IN BRIEF: Fresenius enters licensing pact with Teva Pharmaceuticals